Target Enrichment System Now Supports 454 Life Sciences Next- Generation Sequencing Platform

Agilent Technologies, Inc announced that its SureSelect Target Enrichment System now supports the 454 Life Sciences next-generation sequencing platform, boosting efficiency and cost-effectiveness of research by enabling users to sequence just genomic regions of interest rather than entire genomes. "The SureSelect Target Enrichment Kits are now optimized and validated for all three major next-gen sequencing platforms," said Fred P. Ernani, PhD, Agilent SureSelect Platform Business Manager. "This should drive continued rapid adoption of our target enrichment system by the life sciences community. Accordingly, we will continue to aggressively develop new SureSelect products to help customers address a wider range of important scientific challenges."

In addition to the 454, Agilent SureSelect Target Enrichment is fully compatible with the Illumina Genome Analyser and HiSeq platforms, and Life Technologies’ SOLiD sequencers. The SureSelect kits have been cited in 25 publications this year, covering research into a wide range of heritable disorders. The SureSelect portfolio includes target enrichment for user-specified genomic regions, human kinome, human X chromosome and human all exon sequencing. Agilent’s SureSelect Target Enrichment portfolio offers the industry’s broadest range of target enrichment products and the most highly optimised protocols for a diverse set of sequencing methods and platforms. SureSelect products are available for enrichment of target sizes ranging from smaller than 200 Kb to more than 50 Mb in a single tube.

SureSelect Target Enrichment Kits are easily designed to target any genomic region of interest using Agilent’s eArray design tool, available in desktop or on-line versions.